Tempus AI stock rose more than 9% after announcing xM for treatment response monitoring, TRM, a liquid biopsy assay intended to detect molecular response to immune-checkpoint inhibitor therapy in advanced solid tumors.
xM for TRM is the newest addition to Tempus’ growing portfolio of sensitive assays for monitoring molecular response and minimal residual disease. It is currently available for research use only, with clinical availability expected later this year.
“Our comprehensive monitoring portfolio is designed to support patients throughout the cancer treatment journey,” said Halla Nimeiri, MD, Chief Development Officer at Tempus. “We’re excited to introduce a new assay of molecular response for both physicians and biopharma researchers that can timely track changes of quantitative tumor fraction while patients receive ICI therapies.”
